Is Aurinia Pharmaceuticals' Management Its Best Asset?

Is Aurinia Pharmaceuticals' Management Its Best Asset?

Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus nephritis (LN) patients.

Nowadays, Glickman's at it again as the founder and CEO of Aurinia Pharmaceuticals (NASDAQ: AUPH), a company that's developing voclosporin, a drug that can be used alongside CellCept in the same disease. Can Glickman reshape this indication a second time?

Continue reading

Source: Fool.com